The medtech M&A market is shifting. Instead of many smaller deals, we're seeing a few massive ones. At Superpower, we noticed big companies buying entire firms to get their new technology and data all at once, rather than building it themselves. As new tech develops faster than companies can keep up, I expect we'll see more of these large, targeted buys leading the market.
The medtech deal scene is shifting. We're seeing fewer deals overall, but the ones happening are huge. Companies want tech they can actually put to work, not just buy for the sake of it. At Medix Dental IT, we got more ambitious with our partnerships while staying selective. The real focus now is on digital health and cybersecurity firms, they're right at the center of these big moves.
The PwC report on the U.S. Medtech sector suggests a strategic shift in M&A activity, characterized by a focus on high-value mega-deals rather than numerous smaller transactions. Companies are prioritizing transformative acquisitions aligned with long-term growth, indicating a selective M&A approach. Looking ahead to 2026, the trend is expected to shift towards more frequent, targeted acquisitions aimed at building specific capabilities.
1. High value + low volume usually means buyers only paid up for "must-win" assets and let everything else die in diligence. For 2026, that screams selective M&A: fewer swings, tighter theses, more focus on assets that slot cleanly into a growth narrative and won't blow up integration or regulatory timelines. 2. I expect more frequent, targeted capability buys, with occasional monster deals when the fit is obvious and the market cooperates. The driver is simple: bolt-ons let you add a missing capability fast (software, data, channel, clinical evidence) without betting the company on one integration. 3. Activism accelerates portfolio triage. You'll see companies dump subscale, slower-growth lines faster, then redeploy capital into higher-growth segments where innovation and pricing power are real, not hoped for. 4. Most likely carve-outs: mature, commoditized, operationally heavy product lines and anything that doesn't benefit from the parent's platform. These moves can reshuffle category leadership by freeing focused operators to invest harder in one lane. 5. More PE means more funding for scalable platforms with clear operational upside and repeatable roll-up potential. Expect prioritization of tech that can prove ROI in the field, not just "cool" science. 6. PE-backed platforms will scale by stacking bolt-ons and tightening execution, then selling a cleaner growth story. Valuations will reward real evidence of durable growth, not just deal count. 7. Main targets: AI that improves workflow and decision support, connected-device ecosystems, data infrastructure, and automation in clinical/ops settings. Best assets will have clean data, integration readiness, proof of impact, and defensible distribution. 8. Tariffs/trade uncertainty is the sneaky killer for cross-border because it messes with supply chain math and valuation. Smart buyers are stress-testing scenarios and de-risking sourcing early. 9. Volume likely rebounds, but value can stay lumpy if only a few premium assets trade big while "meh" deals keep getting skipped.
At Advanced Professional Accounting Services, we helped a mid-market medtech client prep for a divestiture by isolating one underperforming hardware line, which lifted EBITDA margin 320 basis points in six months. That pattern explains the high value and low volume mix. In 2026, I expect fewer deals but sharper ones tied to AI diagnostics, remote monitoring, and reimbursement proof. PE will fund platforms that scale fast with clean data and predictable cash flow. Large buyers will pay up for assets that already integrate into care workflows. The gap in deal count versus value will stay widr as conviction beats caution.